Regenerative medicine company Regeneus says it will use a $2.73 million refund from the Australian government's research and development tax incentive program to help progress its product pipeline.
The biomedical company said it had received the money after it's expenditure on eligible R&D activities jumped to 77 per cent during the 2016 financial year, up from 68 per cent a year earlier.
It also expects to be eligible for a further reimbursement for its R&D programs during the 2017 financial year.
Share
